Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 3 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

Cyclophosphamide 44Biopsy 35Specimen Handling 34Magnetic Resonance Spectroscopy 30fludarabine 27aldesleukin 26Filgrastim 20Carboplatin 20Paclitaxel 19fludarabine phosphate 17Rituximab 17Sirolimus 16Cisplatin 16Temozolomide 15Radiotherapy 14Etoposide 14Bevacizumab 14Prednisone 13Gemcitabine 13Docetaxel 13Cytarabine 13Erlotinib Hydrochloride 12Fluorouracil 11Vorinostat 10Vincristine 10Sorafenib 10Electrocardiography 10Doxorubicin 10temsirolimus 9pembrolizumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × NIH × indolepropanol phosphate × Clear all
NCT00354107 2018-03-14

Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
5 enrolled 9 charts
Lymphoid

Lymphoma, Large-Cell, Anaplastic

NCT00086944 2013-01-24

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
25 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡